


REMARKS

Claims 1-9 and 12-16 are active in the present application. Claims 9-11 have been canceled. Claims 3 and 4 have been amended to remove multiple dependencies. Claims 12-16 are new claims. Support for the new claims is found in the original claims and in the specification on page 2, line 19 through page 3, line 26. No new matter is added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Norman F. Oblon
Attorney of Record
Registration No. 24,618

Stefan U. Koschmieder, Ph.D.
Registration No. 50,238



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/SUKOS/js

I:\atty\SUKOS\217550US-PR.wpd

10031371.043003

217550US-0 PCT

Marked-Up Copy

Serial No: _____

Amendment Filed on: 1-18-2002

IN THE CLAIMS

--3. (Amended) A product according to claim 1 [or 2] wherein the antimetabolite compound is a cytidine analog.

4. (Amended) A product according to claim 1 [or 2] wherein the antimetabolite compound is a 5-fluoropyrimidine.

Claims 9-11 (Canceled).

Claims 12-16 (New).

10031371.043002